GeneDock Secures RMB 50 Million Series B Funding to Advance Data-Driven Precision Medicine
The rapid development of emerging data technologies is injecting new vitality into the healthcare industry.
According to VCBeat (WeChat ID: vcbeat), GeneDock (Judaokj) recently announced the completion of its RMB 50 million Series B financing round. The round was led by Morningside Venture Capital, with participation from BGI Genomics, BV Baidu Ventures, and Furong Capital.
Previously, GeneDock secured Series A funding in August 2015, led by Matrix Partners China. A year later, it obtained Series A+ investment from Puhua Capital, Beike Fund, and Legend Star.
In recent years, with the rapid convergence of information technology (IT) and biotechnology (BT), numerous startups have emerged in the field of precision medicine. Among them, GeneDock has uniquely chosen to focus on the research and development of data technologies and platforms for precision medicine, aiming to provide integrated data technology solutions that cover the entire workflow—from information collection and sample testing to analysis and interpretation—tailored to final clinical application scenarios.
“Precision medicine, as we understand it, is a new data-driven model of healthcare that addresses actual clinical needs through the close integration of biotechnology (BT) and information technology (IT). Therefore, precision medicine requires cross-disciplinary convergence of healthcare, BT, and IT in terms of technical methodologies, and demands tight connectivity of business and data flows among upstream and downstream institutions in terms of industrial application. GeneDock has been committed to providing better infrastructure and solutions to facilitate this cross-disciplinary convergence and connectivity,” said Li Xiarong, CEO of GeneDock.
GeneDock was established in September 2014 and has gained widespread industry recognition, starting with its inaugural product, GeneDock SeqFlow (Omics Data Production Line). The rapid advancement of sequencing technologies has generated massive volumes of genomic data, leading to a surge in demand for genomic data storage, analysis, and interpretation. As one of China’s earliest cloud computing services for genomic data, GeneDock SeqFlow has undergone four years of technological research and development as well as product refinement. Its stable, efficient, and secure genomic data processing capabilities now serve numerous leading institutions and enterprises, including BGI Genomics, WeGene, Agitkon, Genetron Health, Sinobioway, and LinkDoc.
Genetic testing and analysis are core technologies for achieving precision medicine, yet they represent only one of the many steps involved in the patient journey from initial consultation to final diagnosis and treatment. Through in-depth collaboration with leading medical institutions and expert teams in China, GeneDock has recognized the immense potential of clinical applications in precision medicine, while also identifying the current industry-wide challenges in business collaboration and data technology. Consequently, in 2017, GeneDock chose to expand its business scope by developing data technology products tailored to the field of precision medicine.
Li Xiarong stated, “We are accelerating the research and development of precision medicine data technologies and products. Building upon our industry-leading gene data production line (GeneDock SeqFlow Omics Data Production Line), we are fully integrating clinical applications (GeneDock Clinic Precision Medicine Workstation), sample testing (GeneDock Lab Intelligent Molecular Diagnostics Laboratory), and analysis and interpretation (GeneDock Link Molecular Diagnostics Collaboration System) to construct a clinical-oriented precision medicine data operating system, while exploring new models for data collaboration.”
Currently, GeneDock is one of the few companies in the industry capable of providing comprehensive business information systems and data platform solutions for precision medicine to physical hospitals. This eliminates the hassle of categorized tendering, procurement, and subsequent integration by hospitals, significantly improving the implementation efficiency of precision medicine systems. Meanwhile, as GeneDock also serves numerous genetic testing enterprise clients, it can standardize and rapidly facilitate upstream and downstream business integration between enterprises and hospitals.
“We position ourselves as a data infrastructure provider in the field of precision medicine, building bridges of interoperability for hospitals and enterprises to facilitate efficient integration across the upstream and downstream segments of the industry,” Li Xiarong stated candidly.
GeneDock’s precision medicine data products have earned a strong reputation in the industry, currently providing precision medicine data platform services to dozens of top-tier medical and research institutions, including the First Affiliated Hospital of Army Medical University (Southwest Hospital), Shanghai Xinhua Hospital, West China Hospital, Shanghai Sixth People’s Hospital, Cancer Hospital of the Chinese Academy of Medical Sciences, Chinese Center for Disease Control and Prevention, Southern Medical University, Academy of Military Medical Sciences, and Institute of Microbiology, Chinese Academy of Sciences, among others.
Advanced and diverse detection technologies have led to an explosive growth in medical data. Faced with this vast amount of information, physicians struggle to make precise analyses and judgments within a short timeframe and are prone to “information fatigue.” GeneDock believes that artificial intelligence (AI) can serve as a powerful information-processing assistant for physicians, alleviating their heavy burden of data processing and returning valuable time to patient care and clinical research. Furthermore, addressing complex and critical conditions such as genetic disorders, tumors, and infectious diseases requires the integration of AI technology to build clinical decision support systems (CDSS), thereby extending and empowering grassroots healthcare providers with the expertise of top clinical specialists. GeneDock is currently collaborating with several expert teams in the industry to develop diagnostic assistance models and decision support systems for specific disease subtypes.
“We remain committed to serving as the data and technology partner for experts in the field of precision medicine, leveraging our respective strengths to jointly develop clinical decision support systems powered by artificial intelligence. This aims to address the slow translation of clinical applications and the uneven distribution of diagnostic and treatment resources, thereby advancing inclusive precision medicine through data intelligence,” said Li Xiarong.
As the lead investor in this funding round, Morningside Venture Capital’s Vice President, Jing Xutian, stated in an interview with VCBeat that one of GeneDock’s greatest strengths is its provision of a comprehensive suite of solutions tailored to gene data-related businesses. Currently, traditional companies engaged in big data mining rarely delve into the genomic sector, and hospitals lack dedicated data systems to support such needs. However, there will be future demand for these solutions. This represents an incremental market in China, and in the United States, where gene data applications are more widespread, we have already witnessed the emergence and growth of companies like DNAnexus.
With the continuous decline in gene sequencing costs in recent years and the irreversible trend toward precision medicine, medical institutions, pharmaceutical companies, and biotechnology firms are increasingly demanding gene sequencing and data analysis services. However, a more fundamental issue remains inadequately addressed: the storage and transmission of genetic data. Given the enormous volume of data generated by gene sequencing, particularly whole-genome sequencing, GeneDock effectively fills this gap. The industry will need companies like GeneDock to serve as infrastructure platforms for precision medicine, connecting medical institutions with technology companies to ensure the storability and mobility of genetic data. Furthermore, vertical applications such as data analysis and interpretation, as well as single-disease prediction models, can be developed on the platform, thereby creating a micro-ecosystem for precision medicine. This is also Jing Xutian’s vision for GeneDock’s future development.
According to Jing Xutian, the investment in GeneDock represents another strategic move by Morningside Venture Capital in the field of bioinformatics. Morningside Venture Capital is optimistic about high-quality startups that leverage computational science and information technology to empower the life sciences sector. Jing Xutian believes that the interdisciplinary convergence will bring significant variable opportunities to the biomedicine field.
BGI Group and GeneDock initially forged ties through collaboration on data services. After each party recognized the other’s product and technical capabilities, they established a strategic partnership. When GeneDock launched a new round of financing, BGI Group swiftly and decisively participated as an investor. Yin Ye, CEO of BGI Group, stated that GeneDock boasts solid technology and a reliable team, making it an outstanding representative in China’s genomic cloud computing sector. From domestically produced sequencers to genomic cloud computing, the world needs Chinese strength. He expressed hope that GeneDock will achieve further breakthroughs in technological innovation and application scenarios.
BV Baidu Venture Capital stated: “BV has long focused on the development of precision medicine driven by genetic data and has invested in numerous Chinese and American startups in fields such as next-generation sequencing technologies, precise gene therapy, and gene-based novel drug discovery. As a platform for hosting and analyzing genetic data, GeneDock is facing a historic opportunity for rapid growth amid the swift increase in the total volume and frequency of use of genetic data. It will also bring lower costs and higher data processing efficiency to the entire industry. As a pioneer in the field of genomic computing, GeneDock has established deep collaborations with many leading hospitals and mainstream genetic companies, including BGI and WeGene. We look forward to the company becoming a leading enterprise among third-party service providers by leveraging genetics, a new data axis with enormous potential.”
Baidu Ventures (BV) is also highly optimistic about the opportunities for new service models and technology-driven innovation arising from the restructuring of the healthcare market structure under the backdrop of China’s new healthcare reforms, and will make further strategic investments in areas such as health informatics, insurance, distribution, and primary care.
Dr. Sun Pengjun, Chairman of Furong Investment, stated that GeneDock has consistently focused on solutions for omics data platforms. With its solid technical capabilities, extensive industry experience, and excellent strategic vision, the company is a rare and high-quality startup in the field of genetic testing. As Furong has long concentrated its investments on China’s healthcare sector, particularly favoring the prospects of precision medicine, this investment was facilitated by such strategic alignment. “Through this investment in GeneDock, we will also inject our own resources—including scientific research, clinical expertise, projects, and talent—into Judao, to help propel GeneDock to become the most valuable precision medicine data platform company in China,” said Dr. Sun Pengjun.